Traverse Biotech II Inc.
New York, NY
- UEI
- JJUSGRQS7RM5
- CAGE
- Not on record
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 708 Greenwich St #4C, New York, NY 10014, USA
- Website
- traversebiotech.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Celdara Medical, LLC | Lebanon, NH | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Mtti | West Chester, PA | 325413 In-Vitro Diagnostic Substance Manufacturing |
| Atux Iskay Group LLC | Plainsboro Township, NJ | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Kibio Inc. | Davis, CA | — |
| Novomedix LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Traverse Biotech II Inc., a woman-owned small business based in New York, New York, develops antibody-drug conjugates and immunotherapy biologics as the prime recipient of federal research grants from the National Institutes of Health, with three SBIR Phase I awards from the National Cancer Institute and the National Institute of Allergy and Infectious Diseases totaling $1.4 million in combined obligation since September 2023.
Traverse is structured as a for-profit corporate entity designated as a woman-owned business. The company's federal footprint consists entirely of prime recipient grants under the SBIR program; the vendor has no contract prime work and no subcontract engagement in the source data. The company's capability portfolio centers on early-stage development of targeted cancer and infectious-disease therapeutics. Recent representative work includes a $399,896 SBIR Phase I award from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) announced September 2026 to develop TB-UA-1, a first-in-class antibody-drug conjugate targeting urokinase plasminogen activator receptor for pancreatic ductal adenocarcinoma treatment, leveraging the company's proprietary INSIDEO bioconjugation technology for stable cytotoxic payload attachment; an SBIR Phase I from the National Institute of Allergy and Infectious Diseases (May 2024, completion October 2026) to develop HPX-612, an orally available NOD2 agonist immunotherapy for visceral leishmaniasis; and an SBIR Phase I from the National Cancer Institute (September 2023, completion August 2024) to advance TB-BS1, a CD3-bispecific antibody targeting ROR2 for non-small-cell lung cancer.
Customer concentration is tight: the National Cancer Institute accounts for two awards and the National Institute of Allergy and Infectious Diseases for one, representing 100% of the source portfolio. Two awards (combined potential value not specified in source) reach ultimate completion inside the next twenty-four months, creating recompete exposure in the near term. Work is performed in New York, New York. The vendor's federal footprint to date is early-stage SBIR, with no movement into Phase II or III contracts or any contract-based development work visible in the source.
Quick answers
Is Traverse Biotech II Inc. registered in SAM.gov?
Yes. Traverse Biotech II Inc.'s SAM.gov registration is active through October 5, 2027.
What is Traverse Biotech II Inc.'s most recent federal award?
Traverse Biotech II Inc.'s most recent federal grant award is Development of a upar-targeting antibody-drug conjugate (ADC) for pancreatic adenocarcinoma (R43CA309866), from National Cancer Institute (NIH), on September 1, 2026.
On GovTribe
See Traverse Biotech II Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors